WARRINGTON, Pa., July 29, 2014 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a specialty
biotechnology company dedicated to advancing a new standard of
respiratory critical care, will report its second quarter 2014
financial results on August 5, 2014
before the open of the U.S. financial markets.
The Company will host a live teleconference and webcast at
9:00 a.m. Eastern Time that same day. During the conference
call, Discovery Labs' management will discuss the 2014 second
quarter financial results along with other business
updates.
The press release and the live webcast of the conference call
will be available via Discovery Labs' corporate website at
www.discoverylabs.com. The webcast will be made available on
the events page. An archive will be available after the call
at the same address until Friday, September
2, 2014.
To participate in the live conference call, please dial (877)
870-4263 (domestic) or (412) 317- 0790 (international). After
placing the call, please ask to be joined into the Discovery Labs
conference call. The conference call replay number is (877)
344-7529 (domestic) or (412) 317-0088 (international); please use
10049810 as the replay passcode.
About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology
company focused on advancing a new standard in respiratory critical
care. Discovery Labs' technology platform includes its novel
proprietary KL4 surfactant, a synthetic, peptide-containing
surfactant that is structurally similar to pulmonary surfactant,
and its proprietary drug delivery technologies being developed to
enable efficient delivery of aerosolized KL4 surfactant and other
inhaled therapies. Discovery Labs' strategy is initially
focused on neonatology and improving the management of respiratory
distress syndrome (RDS) in premature infants. Discovery Labs
believes that its RDS product portfolio has the potential to become
the new standard of care for RDS and, over time, enable the
treatment of a significantly greater number of premature infants
who could benefit from surfactant therapy but are currently not
treated.
For more information, please visit the Company's website at
www.Discoverylabs.com.
SOURCE Discovery Laboratories, Inc.